HAKAMI HOOMAN 4

Accession 0001127602-19-028265

CIK 0001613103other

View on SEC.gov Company Profile

Filed

Sep 11, 8:00 PM ET

Accepted

Sep 12, 5:55 PM ET

Size

48.3 KB

Accession

0001127602-19-028265

Insider Transaction Report

Form 4

Period: 2019-09-10

Medtronic plcMDT

HAKAMI HOOMAN

EVP & Group President Diabetes

Transactions

Sale
Ordinary Shares
2019-09-10$107.08/sh−10,000$1,070,850→ 30,761 total
Exercise/Conversion
Ordinary Shares
2019-09-10$78.00/sh+10,257$800,046→ 41,018 total
Sale
Ordinary Shares
2019-09-10$107.31/sh−10,257$1,100,648→ 30,761 total
Exercise/Conversion
Ordinary Shares
2019-09-10$78.00/sh+321$25,038→ 31,082 total
Sale
Ordinary Shares
2019-09-10$107.28/sh−27,254$2,923,864→ 30,761 total
Sale
Ordinary Shares
2019-09-10$107.22/sh−852$91,351→ 30,761 total
Exercise/Conversion
Ordinary Shares
2019-09-10$83.97/sh+19,054$1,599,964→ 49,815 total
Sale
Ordinary Shares
2019-09-10$107.41/sh−19,054$2,046,666→ 30,761 total
Sale
Ordinary Shares
2019-09-10$107.22/sh−595$63,796→ 30,761 total
Sale
Ordinary Shares
2019-09-10$107.41/sh−14,121$1,516,765→ 30,761 total
Sale
Ordinary Shares
2019-09-10$107.22/sh−423$45,354→ 30,761 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-09-10−852→ 284 total
Exercise: $88.06From: 2017-08-01Exp: 2026-08-01→ Ordinary Shares (852 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-09-10−19,054→ 19,055 total
Exercise: $83.97From: 2018-07-31Exp: 2027-07-31→ Ordinary Shares (19,054 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-09-10−321→ 0 total
Exercise: $78.00From: 2016-08-03Exp: 2025-08-03→ Ordinary Shares (321 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-09-10−14,121→ 42,364 total
Exercise: $89.08From: 2019-07-30Exp: 2028-07-30→ Ordinary Shares (14,121 underlying)
Sale
Ordinary Shares
2019-09-10$107.22/sh−321$34,418→ 30,761 total
Exercise/Conversion
Ordinary Shares
2019-09-10$88.06/sh+27,254$2,399,987→ 58,015 total
Exercise/Conversion
Ordinary Shares
2019-09-10$88.06/sh+852$75,027→ 31,613 total
Exercise/Conversion
Ordinary Shares
2019-09-10$83.97/sh+595$49,962→ 31,356 total
Exercise/Conversion
Ordinary Shares
2019-09-10$89.08/sh+14,121$1,257,899→ 44,882 total
Exercise/Conversion
Ordinary Shares
2019-09-10$89.08/sh+423$37,681→ 31,184 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-09-10−10,257→ 321 total
Exercise: $78.00From: 2016-08-03Exp: 2025-08-03→ Ordinary Shares (10,257 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-09-10−27,254→ 9,085 total
Exercise: $88.06From: 2017-08-01Exp: 2026-08-01→ Ordinary Shares (27,254 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-09-10−595→ 596 total
Exercise: $83.97From: 2018-07-31Exp: 2027-07-31→ Ordinary Shares (595 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-09-10−423→ 1,272 total
Exercise: $89.08From: 2019-07-30Exp: 2028-07-30→ Ordinary Shares (423 underlying)

Footnotes (7)

[F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
[F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.00 to $107.39, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
[F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.10 to $107.43, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
[F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.07 to $107.47, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
[F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.28 to $107.58, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
[F6]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.36 to $107.48, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
[F7]These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

Medtronic plc

CIK 0001613103

→

Entity typeother

Related Parties

filerCIK 0001610035

Filing Metadata

Form type: 4
Filed: Sep 11, 8:00 PM ET
Accepted: Sep 12, 5:55 PM ET
Size: 48.3 KB

View on SEC.gov